NLS Pharmaceutics (NLSP) provided insights into the preclinical program evaluating its dual orexin receptor agonist platform. AEX-41 and AEX-2, two first-in-class non-sulfonamide DOXAs, are designed ...
ZÜRICH, Switzerland, Feb. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NLSP) (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), in collaboration with Aexon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results